Effect of ivabradin on heart rate, left ventricular function a NT-proBNP concentration in patients with systolic chronic heart failure –⁠ case reports

Czech version

Authors: F. Málek
Authors‘ workplace: Kardiovaskulární centrum Nemocnice Na Homolce Praha, přednosta prim. MUDr. Štěpán Černý, CSc.
Published in: Vnitř Lék 2012; 58(10): 779-783
Category: Case Reports

Overview

Ivabradin is indicated in patients with compensated chronic heart failure and sinus rhythm with resting heart rate ≥ 75 beats per minute despite maximal tolerated beta-blocker dose. Three case reports show favourable effect of ivabradin therapy on heart rate, reverse cardiac remodeling and B-type natriuretic peptide concentration in patients with systolic heart failure.

Key words:
chronic heart failure –⁠ ivabradin –⁠ heart rate –⁠ cardiac remodeling –⁠ B-type natriuretic peptide

Sources

1. Diaz A, Bourassa MG, Guertin MC et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26 : 967–974.

2. Fox K, Ford I, Steg PG et al. BEAUTIFUL Investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction: a subgroup analysis of a randomised controlled trial. Lancet 2008; 372 : 817–821.

3. Flannery G, Gehrig-Mills R, Billah B et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008; 101 : 865–869.

4. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial. Lancet 2010; 376 : 875–885.

5. Ekman I, Chassany O, Komajda M et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 2011; 32 : 2395–2404.

6. Tardif JC, O’Meara E, Komajda M et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 2011; 32 : 2507–2515.

7. Špinar J, Vítovec J, Hradec J et al. Doporučení pro diagnostiku a léčbu chronického srdečního selhání České kardiologické společnosti 2011. Vnitř Lék 2012; 58 (Suppl 1): 1S4–1S40.

8. McMurray JJ, Adamopoulos S, Anker SD et al. Task Force Members. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14 : 803–869.